0.34 (-%)
As of Nov 20, 2024
Source:
TransCode is an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | 857-301-6857 |
| Industry | |
| CEO | Thomas A. Fitzgerald |
| Website | www.clinicaltrials.gov |